1,219,081 Shares in IQVIA Holdings Inc. $IQV Bought by Bank of America Corp DE

Key Points

• Bank of America acquired 1.22 million IQVIA shares worth approximately $235.6 million, while institutional investors collectively own 89.62% of the company. BlackRock also initiated a substantial position valued at about $2.81 billion.
• IQVIA reported quarterly earnings of $3.15 per share, exceeding estimates of $3.03, while revenue rose 8.7% year over year to $4.37 billion. The company issued fiscal 2026 EPS guidance of $12.80–$13.00.
• Analysts maintain a positive outlook, with a consensus “Moderate Buy” rating and an average price target of $243.62; however, insiders sold 15,581 shares worth approximately $3.8 million over the past three months.

Bank of America Corp DE bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 1,219,081 shares of the medical research company's stock, valued at approximately $235,551,000. Bank of America Corp DE owned about 0.74% of IQVIA at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of IQV. BlackRock Inc. bought a new position in shares of IQVIA during the second quarter valued at approximately $2,811,292,000. Geode Capital Management LLC grew its position in shares of IQVIA by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company's stock worth $982,272,000 after acquiring an additional 24,453 shares during the last quarter. Boston Partners grew its position in shares of IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock worth $923,276,000 after acquiring an additional 530,672 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 16.2% in the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock worth $856,468,000 after acquiring an additional 528,753 shares during the period. Finally, Norges Bank bought a new stake in IQVIA in the 4th quarter valued at about $497,445,000. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider James G. Berkshire sold 2,668 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company's stock, valued at $2,845,883.70. The trade was a 19.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,581 shares of company stock valued at $3,796,021 over the last three months. 1.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

IQV has been the topic of several analyst reports. HSBC restated a "buy" rating and issued a $240.00 price target on shares of IQVIA in a research note on Monday, July 6th. Stifel Nicolaus raised their target price on IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. lifted their target price on IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research note on Thursday, July 9th. Finally, Royal Bank Of Canada increased their target price on shares of IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average target price of $243.62.

IQVIA Stock Performance

Shares of NYSE IQV opened at $269.54 on Thursday. The stock's fifty day simple moving average is $240.29 and its 200 day simple moving average is $198.32. The stock has a market capitalization of $44.37 billion, a price-to-earnings ratio of 33.44, a PEG ratio of 2.30 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $273.56.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the prior year, the business posted $2.81 earnings per share. IQVIA's revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.